Alliance is a speciality pharmaceutical group based in the United Kingdom and listed on AIM.  The group was founded in 1998 and since then has established a strong track record of acquiring the rights to established niche products. Alliance now owns or licences over 50 prescription products.  Pro forma annual sales now exceed £40m.


Alliance maintains strategic and controlling functions with a management team possessing considerable large pharmaceutical company experience. More labour and capital intensive functions are outsourced to maximise efficiency and profitability.

The core of Alliances' activities are in the United Kingdom and the Republic of Ireland. The group also sells into approximately 20 other countries Worldwide, including via a joint venture into China.

Alliance Pharmaceuticals is a member of the ABPI (Association of the British Pharmaceutical Industry) www.abpi.org.uk and the PAGB (Proprietary Association of Great Britain) www.pagb.org.uk.

Key Products

DELTACORTRIL

An enteric coated tablet formulation of the steroid prednsiolone. DELTACORTRIL was acquired from Pfizer in 2006. It is indicated for a wide range of inflammatory and allergic disorders. This product range has grown substantially since acquisition.

NU-SEALS

An enteric-coated aspirin tablet. The majority of sales are for the 75mg version sold in the Republic of Ireland. This product is principally used as an anti clotting agent prescribed to prevent heart attacks and strokes. NU-SEALS was acquired from Lilly in 2002 and since then its sales have grown substantially.

FORCEVAL

FORCEVAL capsules are a vitamin and mineral supplement. The majority of sales come from the UK and China markets. In the UK FORCEVAL is in the main prescribed for nutritional deficits caused by disease or restricted diets. The capsules are also available over the counter.

The largest single potential market for FORCEVAL however is China. Here it is has been adopted by some state family planning clinics as a supplement for women planning or having a baby. The aim is to prevent birth defects. FORCEVAL was acquired by Alliance in 2004 and since then its sales have grown substantially.

IMMUCYST

An immunotherapy based on the BCG bacillus. IMMUCYST is instilled into the bladder of people suffering from superficial bladder cancer or following surgical removal of bladder tumours. The product causes an acute local inflammatory and immune response as a result of which white blood cells infiltrate the bladder and attack the cancerous cells. This product was acquired with Cambridge laboratories in 2010. Since then strong growth has continued.

HYDROMOL

HYDROMOL is the brand name for a range of emollient products. The range includes ointments, creams and bath additives. These products are principally prescribed in the UK to treat common dry skin conditions such as Eczema and Psoriasis. HYDROMOL was acquired from Ferndale in 2006 and since then its sales have tripled.

Established Products

The established products business is our core business. We acquire good, substantial products that continue to meet medical needs. In the UK we have become a leader in the acquisition and management of established products. These products typically grow modestly without active promotion as market demand increases due to changing demographics. The risk of attrition due to competition has usually already occurred or is limited for these products. The value of these product assets is sustained through our ability to keep them up to date and maintain continuity of supply.

Having acquired these products’ our team has a unique collection of skills to selectively make medicines better and breathe new life into them. BUCCASTEM, DELTACORTRIL and NU-SEALS are just some of the products that have benefitted from this extra treatment and additional value has been extracted.

Depending on the elements of the marketing mix required these products may find their way into our related business units or into partnerships with other players. Whatever the case our aim is to maximise the value of the acquired assets for our shareholders.

For further information on establised products please click here 

Dermatology

The Dermatology Business Unit has evolved out of our core established products business and has allowed Alliance to broaden its portfolio through the acquisition of selected dermatological products. These include treatments for eczema, psoriasis, ichthyosis, acne, warts and irritated skin.

The acquisition and subsequent promotion of the Hydromol range has proved particularly successful with sales tripling over the last 4 years. The HYDROMOL Range consists of HYDROMOL Bath and Shower Emollient, HYDROMOL Cream, HYDROMOL Ointment and HYDROMOL Intensive.

Further information can be found on the HYDROMOL website www.hydromol.co.uk

The addition of TIMODINE to the dermatology business in 2009 is an example of Alliance’s continued ambition to expand its portfolio and establish itself in the dermatology market.

International 

The International business at Alliance Pharmaceuticals is responsible for c£9m in annual sales. Key international markets are China and the Republic of Ireland.

In addition we sell our products in over 25 territories. Key international brands are NU-SEALS and FORCEVAL. The International business has grown historically through acquisitions of business and products and the development of a network of distributors.

Cambridge Laboratories 

The acquisition of Cambridge Laboratories in 2010 enabled Alliance to broaden its business strategy with a specialist business unit focused on the promotion and supply of specialist secondary care medicines. It provides full and direct key account coverage to hospitals across the UK, specifically in the therapeutic areas of urology and oncology.

The Cambridge products include the BCG immunotherapy brand IMMUCYST 81MG, which is for the treatment of non invasive bladder cancer. Non muscle invasive bladder cancer accounts for 70% of diagnosed bladder cancer in the UK.

Further information can be found on the IMMUCYST 81MG website www.immucyst.com

Other products include GELCLAIR, for the management of chemotherapy and radiotherapy induced oral mucositis, a painful and debilitating side effect of cancer treatments.

Further information can be found on the GELCLAIR website www.gelclair.co.uk